Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 8Brain Neoplasms 8Neoplasm Metastasis 4Meningeal Carcinomatosis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × trastuzumab deruxtecan × CNS × Clear all
NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡